1423058-85-8 Usage
Description
BRD9757 is a potent and selective HDAC6 inhibitor with an IC50 value of 30 nM. It demonstrates a high degree of selectivity for HDAC6 over both Class I HDACs (more than 20-fold) and Class II HDACs (more than 400-fold). This characteristic makes BRD9757 a valuable compound for various applications in different industries.
Uses
Used in Pharmaceutical Industry:
BRD9757 is used as a potent HDAC6 inhibitor for the development of therapeutic strategies targeting various diseases. Its high selectivity for HDAC6 over other HDACs makes it a promising candidate for the treatment of conditions where HDAC6 plays a significant role, such as cancer and neurodegenerative diseases.
Used in Research and Development:
In the field of research and development, BRD9757 is used as a valuable tool to study the role of HDAC6 in various biological processes. Its high selectivity allows researchers to investigate the specific functions and interactions of HDAC6 without interference from other HDAC isoforms, leading to a better understanding of its role in disease pathology and potential therapeutic applications.
Used in Drug Discovery and Development:
BRD9757 is employed as a lead compound in the development of new drugs targeting HDAC6. Its potent inhibitory activity and selectivity make it an attractive starting point for the design and optimization of novel HDAC6 inhibitors with improved pharmacological properties, potentially leading to the development of more effective treatments for diseases associated with HDAC6 dysregulation.
Used in Chemical Biology:
In the field of chemical biology, BRD9757 serves as a valuable probe to explore the cellular functions and pathways regulated by HDAC6. Its high selectivity enables researchers to dissect the complex networks of protein interactions and signaling events mediated by HDAC6, providing insights into the molecular mechanisms underlying its role in various biological processes and diseases.
Overall, BRD9757 is a versatile compound with a wide range of applications in the pharmaceutical, research and development, drug discovery, and chemical biology industries. Its potent and selective inhibition of HDAC6 makes it a valuable tool for the development of novel therapeutic strategies and a promising candidate for the treatment of diseases associated with HDAC6 dysregulation.
Check Digit Verification of cas no
The CAS Registry Mumber 1423058-85-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,2,3,0,5 and 8 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1423058-85:
(9*1)+(8*4)+(7*2)+(6*3)+(5*0)+(4*5)+(3*8)+(2*8)+(1*5)=138
138 % 10 = 8
So 1423058-85-8 is a valid CAS Registry Number.
1423058-85-8Relevant articles and documents
Formal Lossen Rearrangement/[3+2] Annulation Cascade Catalyzed by a Modified Cyclopentadienyl RhIII Complex
Yamada, Takayuki,Shibata, Yu,Kawauchi, Susumu,Yoshizaki, Soichi,Tanaka, Ken
supporting information, p. 5723 - 5727 (2018/04/11)
It has been established that a cyclopentadienyl RhIII complex with two phenyl groups and a pendant amide moiety catalyzes the formal Lossen rearrangement/[3+2] annulation cascade of N-pivaloyl benzamides and acrylamides with alkynes leading to substituted indoles and pyrroles. Mechanistic studies revealed that this cascade reaction proceeds via not the Lossen rearrangement to form anilides or enamides but C?H bond cleavage, alkyne insertion, and the formal Lossen rearrangement.
